Kana Ichikawa

Kana Ichikawa is a seasoned Senior Scientist in Biology at Foghorn Therapeutics, Inc. since June 2019, with a strong focus on immuno-modulatory therapies and drug discovery. Key achievements include discovering the properties of the BRM/BRG1 inhibitor FHD-286 and leading pre-clinical evaluations of combination therapies, alongside managing in vivo studies to elucidate drug mechanisms and cellular impacts on the tumor microenvironment. Previous experience at Moderna involved oncology research and assay development, while early roles at H3 Biomedicine focused on target biology and kinase inhibition studies. An initial career phase at IMS Health encompassed market analysis in various therapeutic areas. Kana Ichikawa holds a BA in Psychology and Biology from Cornell University and a Master’s degree in Biology from Harvard Extension School.